Extensive-Stage Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer (ES SCLC) is a fast-growing type of lung cancer that has spread beyond the lungs to other parts of the body, making it more challenging to treat.
Extensive-Stage Small-Cell Lung Cancer: THOR Trial
We are studying a combination of chemotherapy, pembrolizumab, and olaparib for patients with extensive-stage small-cell lung cancer. The goal is to see if this approach improves survival and response rates compared to standard treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of extensive stage small cell lung cancer (SCLC)?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications that are strong CYP3A inhibitors like itraconazole or clarithromycin?
- Have you had any major surgery in the past 4 weeks?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Aedon
Anzorin
Arenbil
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Istituto Tumori Bari Giovanni Paolo II
SSD Oncologia medica patologie toraciche
Bari, Italy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
U.O. Oncologia
Bologna, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Oncologia medica
Meldola, Italy
Sponsor: Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.